Tilray Brands said it has increased annual cultivation capacity to approximately 275 metric tons, up from 210 metric tons, driven by expanded output at its Quebec facility in Canada and its EU-GMP-certified facility in Portugal.
“Tilray is defining what global leadership in cannabis looks like. We are expanding production across Canada and Europe, increasing global capacity to approximately 275 metric tonnes, and strengthening the supply infrastructure needed to serve patients and partners across the world’s most important medical cannabis markets. As demand accelerates, Tilray is leading with scale, discipline and a differentiated international platform built for long-term growth," said Tilray CEO Irwin D. Simon in a statement.
The company has increased annual cultivation capacity at its Quebec facility by 30 metric tons, materially increasing inventory for the Quebec market while adding supply for Europe, Australia and other regulated international markets. The Quebec facility is also on track to achieve EU-GMP certification within the next 12 months.
Tilray is now shipping Quebec-grown bulk cannabis directly to its sites in Portugal and Australia. The Company has also increased output at its EU-GMP-certified Portugal facility, one of Europe’s largest medical cannabis production sites and the anchor of Tilray’s European supply chain, strengthening supply to Germany, the United Kingdom and other European markets. In Germany, Tilray has also strengthened its cultivation operations, with its Aphria RX facility fully utilized and its new ARX brand launched successfully with strong early patient response.
The expansion of Tilray’s international cannabis operations further strengthens its position as a global cannabis leader. As an industry pioneer, Tilray continues to lead with a differentiated global platform that connects scaled cultivation, pharmaceutical distribution and vertically integrated patient-access platforms, including HelloMD in Canada and Lyphe Clinic in the United Kingdom, to expand access across the world’s most important medical cannabis growth markets.
